GIM
ANIK icon

Glenmede Investment Management’s Anika Therapeutics ANIK Stock Holding History

Glenmede Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,220
Closed -$12.9K – 1450
2025
Q2 		$12.9K Buy
+1,220
New +$15.4K ﹤0.01% 1446

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Investment Management's ANIK Position: Q3 2025 in Review

Glenmede Investment Management sold out of Anika Therapeutics (ANIK) in Q3 2025, closing a stake of 1,220 shares — an estimated $12.9K sold.

Glenmede Investment Management first reported a position in ANIK in Q2 2025 and held it in 1 quarter. The position peaked at $12.9K in Q2 2025. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

  • Glenmede Investment Management reported no remaining Anika Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 1,220 Anika Therapeutics shares in Q3 2025, an estimated $12.9K.
  • Glenmede Investment Management first reported a position in Anika Therapeutics in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Anika Therapeutics position peaked at $12.9K in Q2 2025.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.